Positive data from pivotal phase III study could improve standard of care for Hodgkin lymphoma patients

7 diciembre 2014

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care, researchers report.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/GmNplJqjEFs/141207091426.htm